Pfizer's Bourla Urges Patience As COVID-19 Vaccine Data Timeline Lags
Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.
You may also be interested in...
Pfizer's vaccine for COVID-19 outpaced expectations on efficacy, driving a stock market rally and garnering reaction from Vice President Pence and President-elect Biden.
The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.
Merck has already paused other studies testing the potential first-in-class NRTTI and is adding additional monitoring of lymphocyte and CD4+ T-cell assessments.